PMID- 1382479
OWN - NLM
STAT- MEDLINE
DCOM- 19921102
LR  - 20211203
IS  - 1044-1549 (Print)
IS  - 1044-1549 (Linking)
VI  - 7
IP  - 4
DP  - 1992 Oct
TI  - Interleukin-8 and RANTES inhibit basophil histamine release induced with monocyte 
      chemotactic and activating factor/monocyte chemoattractant peptide-1 and 
      histamine releasing factor.
PG  - 427-33
AB  - The objective of this study was to investigate the effect of interleukin-8 (IL-8) 
      and RANTES on basophil histamine release induced with monocyte chemoattractant 
      peptide-1 (MCP-1) and crude histamine releasing factor (HRF). IL-8 induced low 
      levels of histamine release (8.5 +/- 0.5%) from basophils obtained from only six 
      of 20 donors at high concentrations (10(-6) M). RANTES induced histamine release 
      (16 +/- 2%) from basophils of four of 15 donors at 10(-7) M concentration. 
      However, both IL-8 and RANTES inhibited MCP-1 and HRF-induced histamine release 
      from basophils dose-dependently at concentrations of 10(-9) to 10(-7) M. 
      Basophils from all donors showed a significant inhibitory response (greater than 
      15%). The maximal inhibition of MCP-1 and HRF by IL-8 was 28 +/- 4% and 48 +/- 
      8%, respectively. The maximal inhibition of MCP-1 and HRF by RANTES was 26 +/- 4% 
      and 43 +/- 6%, respectively. Peripheral blood mononuclear cell-derived HRF was 
      purified into three distinct peaks by reverse-phase high performance liquid 
      chromatography. Peak I contained MCP-1 as judged by binding to an immunoaffinity 
      column that was prepared with anti-MCP-1 antibody. IL-8 inhibited histamine 
      release induced with all three peaks of HRF. The inhibition of histamine release 
      by IL-8 was significantly higher in normal subjects than in allergic patients (59 
      +/- 9% versus 31 +/- 7%, P less than 0.05). Both IL-8 and RANTES inhibited 
      cytokine-induced histamine release only and did not affect histamine release by 
      anti-IgE, FMLP, and C5a.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Alam, R
AU  - Alam R
AD  - Department of Medicine, University of Texas Medical Branch, Galveston 77550.
FAU - Forsythe, P A
AU  - Forsythe PA
FAU - Lett-Brown, M A
AU  - Lett-Brown MA
FAU - Grant, J A
AU  - Grant JA
LA  - eng
GR  - AI22940/AI/NIAID NIH HHS/United States
GR  - AI27864/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Respir Cell Mol Biol
JT  - American journal of respiratory cell and molecular biology
JID - 8917225
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Chemotactic Factors)
RN  - 0 (Interleukin-8)
RN  - 0 (Lymphokines)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Tumor Protein, Translationally-Controlled 1)
RN  - 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine)
SB  - IM
MH  - Anti-Infective Agents/pharmacology
MH  - Basophils/drug effects/*physiology
MH  - *Biomarkers, Tumor
MH  - Cell Separation
MH  - Chemokine CCL2
MH  - Chemokine CCL5
MH  - Chemotactic Factors/*pharmacology
MH  - Chromatography, High Pressure Liquid
MH  - Histamine Release/*drug effects
MH  - Humans
MH  - Hypersensitivity
MH  - In Vitro Techniques
MH  - Interleukin-8/*pharmacology
MH  - Leukocytes/cytology/pathology/physiology
MH  - Lymphokines/*pharmacology
MH  - N-Formylmethionine Leucyl-Phenylalanine/pharmacology
MH  - Recombinant Proteins/pharmacology
MH  - Reference Values
MH  - Tumor Protein, Translationally-Controlled 1
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
AID - 10.1165/ajrcmb/7.4.427 [doi]
PST - ppublish
SO  - Am J Respir Cell Mol Biol. 1992 Oct;7(4):427-33. doi: 10.1165/ajrcmb/7.4.427.